1,720,982 research outputs found
Importance of the Watzke-Allen test in diagnostics and staging of macular holes
No full textThe Watzke-Allen test (WAT) is a simple diagnostic tool designed for the diagnosis of full thickness macular holes (FTMH) but due to the rapid progress of imaging diagnostics it was replaced by spectral domain optical coherence tomography (SD-OCT) of macular pathologies. The aim of this study was to examine if the WAT is able to distinguish between the different FTMH stages. In 57 eyes of 57 patients with clinical evidance of FTMH, the WAT was first performed followed by SD-OCT examination and a distinction was made between a negative (slit beam normal) and a positive sign (slit beam modified as groove and hourglass configuration or completely broken). In 49 out of 57 patients the WAT was positive (hourglass 46 patients and broken 3 patients). Based on the SD-OCT results the following diagnoses were made: lamellar macular holes (LMH, 3 patients), vitreomacular traction (VMT, 4 patients), small macular hole (a parts per thousand currency signaEuro parts per thousand 250 A mu m, 5 patients), medium sized macular hole (250-400 A mu m, 11 patients) and large macular hole (a parts per thousand yenaEuro parts per thousand 400 A mu m, 34 patients). In 91 % of the patients with medium and large FTMH, the WAT was positive, whereas the WAT was positive in only 67 % of patients with small FTMH, VMT and LMH. The sensitivity for large and medium FTMH was 93 % but the specificity was only 33 %. The WAT was positive in a high percentage of patients with large and medium sized macular holes as well as patients with small macular holes and LMH. The sensitivity of certain indications for treatment was 93 % but the specificity was only 33 %; therefore, the WAT alone is not suitable for a certain preoperative differentiation of macular alterations
Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy
No full textTo date, there is no consensus about the management of persistent cystoid macular edema (CME) following vitrectomy. The aim of this study was to evaluate the efficacy and safety of intravitreal dexamethasone implants for the treatment of postoperative CME following vitrectomy. In this multicenter study we retrospectively reviewed the data of 24 patients (25 eyes) who had been treated with intravitreal dexamethasone (OzurdexA (R)) for the management of persistent postoperative CME following pars plana vitrectomy. The main outcome measure was central retinal thickness (CRT in A mu m) as assessed by spectral domain optical coherence tomography (SD-OCT). Secondary outcome measures included change in best corrected visual acuity (BCVA) and the presence of metamorphopsia. All 19 eyes which were postoperatively examined within 4-8 weeks after implantation showed a significant decrease in CRT (mean 564 A mu m to 315 A mu m) and a reduction of metamorphopsias. Within the same period of time the BCVA improved in 15 out of 19 eyes (79%) which corresponds to an average visual improvement from 0.69 logMAR to 0.46 logMAR (P < 0.0001). In eyes examined after 10-16 weeks a slight increase in the average CRT of 351 A mu m was observed, whereas the BCVA improved to 0.28 logMAR. After 4 months a decrease in average BCVA was noted. Out of 25 eyes 12 required further dexamethasone implantations between 1 and 4 times within the investigation period. The first repeat injections were performed an average of 7.3 months after the initial treatment. Our results suggest that intravitreal dexamethasone is a safe and effective treatment option for persistent CME following vitrectomy
Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study
No full textIs micropulse diode laser photocoagulation effective in treating recalcitrant chronic central serous chorioretinopathy?
No full textPredictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment
No full textThe study analyses patients' risk factors to determine prognostic and predictive factors in patients with acute central retinal artery occlusion (CRAO) treated in the randomized European Assessment Group for Lysis in the Eye (EAGLE) Study with local intra-arterial fibrinolysis (LIF) or conservative standard treatment (CST). These data could improve patient selection for either method. Post hoc statistical analysis of effects of risk factors on overall best corrected visual acuity (BCVA [logarithm of the minimum angle of resolution (logMAR)]) at baseline and month 1 (prognostic effect) and on the difference between outcome of CST and LIF (predictive effect) was conducted. Seventy two of 84 EAGLE datasets were included. Prognostic effect: Patients with coronary heart disease (CHD) presented worse BCVA at baseline (0.39 logMAR, p = 0.0097). Patients with time from occlusion to treatment 70 years favours CST 0.28 logMAR; interaction p = 0.070) and CHD (favours CST 0.44 logMAR; interaction p = 0.073) might be predictors of therapeutic outcome. There were no strong effects in multivariate analysis. CHD, time from occlusion to treatment and smoking influence BCVA at baseline and at month 1 (prognostic effect). Patients treated within 12 h are more likely to profit from treatment. In multivariate analysis, there is no clear trend to benefit from LIF even in patients with young age, no CHD and early treatment. Based on this preliminary report on a rather small sample size, we do not recommend LIF in CRAO patients
- …
